A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT -methylated malignant glioma.

Riley K Driscoll Seán B Lyne David J VoceStefania MarakaVinai GondiSteven J Chmura Karan S Dixit Priya U KumthekarTheodore G KarrisonPeter PytelJohn M CollinsRoger StuppRyan T MerrellRimas V Lukas Bakhtiar Yamini

Published in: Neuro-oncology advances (2024)

methylated GBM and support examination of acetazolamide in a randomized trial. BCL-3 expression is a potential biomarker for prognosis in GBM or for patients more likely to benefit from TMZ.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
poor prognosis
chronic kidney disease
prognostic factors
peritoneal dialysis
binding protein
patient reported outcomes
long non coding rna